Long-Lasting Exendin-4 Fusion Protein Improves Memory Deficits in High-Fat Diet/Streptozotocin-Induced Diabetic Mice
Glucagon-like peptide 1 (GLP-1) mimetics have been approved as an adjunct therapy for glycemic control in type 2 diabetic patients for the increased insulin secretion under hyperglycemic conditions. Recently, it is reported that such agents elicit neuroprotective effects against diabetes-associated...
Main Authors: | Kyung-Ah Park, Zhen Jin, Jong Youl Lee, Hyeong Seok An, Eun Bee Choi, Kyung Eun Kim, Hyun Joo Shin, Eun Ae Jeong, Kyoung Ah Min, Meong Cheol Shin, Gu Seob Roh |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/12/2/159 |
Similar Items
-
Exendin-4 Pretreatment Attenuates Kainic Acid-Induced Hippocampal Neuronal Death
by: Yu-Jeong Ahn, et al.
Published: (2021-09-01) -
Comparison of desferrioxamine and NODAGA for the gallium-68 labeling of exendin-4
by: Simon A. M. Kaeppeli, et al.
Published: (2019-05-01) -
Exendin-4 for Parkinson's disease
by: Felipe de Jesús Esparza-Salazar, et al.
Published: (2021-01-01) -
Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study
by: Dandan Mao, et al.
Published: (2021-03-01) -
Radiosynthesis and evaluation of an 18F–labeled silicon containing exendin-4 peptide as a PET probe for imaging insulinoma
by: Lukas O. Dialer, et al.
Published: (2018-01-01)